Bromantane · Research brief

Is Bromantane Safe? What Bromantane Research Shows

Real Peptides Research TeamEditorial

Updated September 30, 202611 min read

56 WORDS

Short answer

Bromantane didn't enter Western science through a pharmaceutical pipeline. It arrived through a doping scandal at the 1996 Atlanta Olympics, where Russian athletes tested positive for a compound most Western pharmacologists had never heard of. The Court of Arbitration for Sport cleared them, because the substance wasn't on the prohibited list yet. That gap closed fast.

Key takeaways

Bromantane is N-(2-adamantyl)-N-(4-bromophenyl)amine, formula C16H18BrN, molecular weight roughly 304 g/mol, and is a small molecule rather than a peptide.
The mechanism described in the literature is increased dopamine synthesis via tyrosine hydroxylase and aromatic L-amino acid decarboxylase, not dopamine reuptake inhibition.
Bromantane human studies are concentrated in Russian-language clinical literature on asthenic disorders, with no FDA or EMA review and no published large English-language randomised controlled trial.
The compound is prohibited in competitive sport as a stimulant, a ruling that followed the 1996 Atlanta Olympics and reflects competition integrity rather than toxicology.
No established human dose exists, and published bromantane research does not support safety claims for consumption in any form.
Batch-specific HPLC purity and mass spectrometry identity documentation is the only meaningful proof that what's in the vial matches the label.

That's the awkward origin of modern bromantane research: a Soviet-era actoprotector the West met as a detection problem before it met it as pharmacology. We supply this compound to laboratories. The question we field most often isn't about mechanism. It's about what the evidence base actually contains, and how much weight it can carry.

Is bromantane safe?

Bromantane research does not establish safety for human use. The compound is an unapproved adamantane derivative whose clinical record sits almost entirely in Russian-language literature, with no FDA or EMA review and no large independent replication. It is supplied strictly for laboratory research by qualified investigators, never for consumption.

The common misreading is that registration in one country functions as a global safety clearance. It doesn't. National registration reflects one regulator's evidentiary standard at one moment in time, and it says nothing at all about the identity or purity of material sold today as a bromantane research chemical. What follows covers the pharmacology the published work describes, what the human trial record actually contains, the anti-doping and regulatory position, and how labs verify and store the material.

An adamantane derivative with a Soviet-era paper trail

Bromantane is N-(2-adamantyl)-N-(4-bromophenyl)amine, a small lipophilic molecule with the formula C16H18BrN and a molecular weight of roughly 304 g/mol. It also appears in the literature as ADK-709 and under the Russian trade name Ladasten. Development traces back to Soviet pharmacology programmes of the 1980s, where it was classified as an actoprotector: a category for agents intended to sustain physical and mental work capacity under stress without the oxygen cost associated with classical stimulants. That category has no clean Western regulatory equivalent, which is one reason bromantane research is difficult to slot into a familiar drug class.

The practical point for anyone sourcing bromantane for research is that this is not a peptide. There's no amino acid sequence to verify, no lyophilised cake, no reconstitution step with bacteriostatic water, and no cold chain requirement in transit. Identity is confirmed by molecular formula, CAS registry number and mass spectrometry; purity is confirmed by HPLC.

Our team has watched labs apply peptide handling habits to small molecules and manufacture problems that never existed, mostly by over-refrigerating working stock so that condensation forms on the vial every time it's opened. Most English-language bromantane research summaries skip the handling question entirely, which is unfortunate, because it's the part a working lab actually has to get right.

The mechanism the published work actually describes

The dominant mechanistic account in bromantane research is indirect dopaminergic action at the level of biosynthesis. Published work describes upregulated expression and activity of tyrosine hydroxylase, the rate-limiting enzyme that converts L-tyrosine into L-DOPA, alongside aromatic L-amino acid decarboxylase, which converts L-DOPA into dopamine. The reported effect is increased dopamine synthesis capacity in hypothalamic regions rather than blockade of the dopamine transporter, which is how amphetamine-type stimulants and methylphenidate operate.

That distinction matters far more than most summaries admit. A reuptake inhibitor produces an acute, dose-linked rise in synaptic dopamine. A synthesis-side modulator acting through enzyme expression produces a slower, cumulative shift, which is why animal work describes effects building across repeated administration rather than appearing within an hour of a single dose.

Here's the consequence nobody flags: a research team that designs a single-dose behavioural assay around a classical stimulant time course can miss the signal completely and conclude the compound is inert. It is the most common design error we see raised in bromantane research enquiries, and it has nothing to do with compound quality.

The literature also reports an anxiolytic component, with proposed GABAergic and neuroimmune contributions. Research suggests this combination of mild activation without the anxiety load typical of catecholamine releasers is the compound's most distinctive reported property. The supporting work is limited, largely preclinical, and should be read as a hypothesis rather than a settled mechanism.

What bromantane research in humans does and doesn't show

Bromantane human studies exist, but the record is considerably narrower than most write-ups imply. Clinical work was carried out in Russia on asthenic disorders, and the compound was registered there as Ladasten for asthenia; Russian clinical literature also reports investigation in generalised anxiety. Those publications sit mainly in Russian-language journals, tend to be small, were conducted within a single national research tradition, and have rarely been replicated by independent groups outside it.

No FDA or EMA review exists. There is no Western phase III programme, no large multicentre randomised controlled trial published in English, and no systematic review or meta-analysis of the kind that would let anyone state effect sizes with confidence. Absence of published harm is not a safety record.

The honest framing of bromantane research in humans is that the compound has a clinical history rather than a clinical evidence base. Those are different things, and the gap between them is where most confident internet claims live.

So when a search for bromantane benefits holistic research or bromantane elite research surfaces assured statements about cognition, fatigue or mood, follow the citation. In our experience handling sourcing questions from research groups, the chain usually terminates in the same small cluster of Russian papers, a secondary review summarising them, or a forum post that paraphrased both.

Doping bans, controlled-substance status and what 'safe' really means

Bromantane appears on the World Anti-Doping Agency prohibited list under the stimulant category, a listing that followed the Atlanta fallout. That's a competition-integrity decision, not a toxicology verdict, and conflating the two is a recurring error in bromantane research discussions. A substance can be banned in sport and barely characterised toxicologically at the same time.

On safety specifically, the published adverse-event picture comes from that same limited Russian clinical work, which generally described the compound as well tolerated in the populations studied. That sentence carries heavy qualifiers for good reason. Tolerability in a small, monitored trial cohort says very little about chronic exposure, drug interactions, or effects in people with cardiac, hepatic or psychiatric conditions. No compound with a dopaminergic mechanism should be assumed neutral in those contexts.

Material sold as a bromantane research chemical adds a second, independent risk layer: identity and purity. A compound with a tidy literature profile and an unverified batch is not a clean compound, and no amount of published pharmacology compensates for an unknown solid in a vial.

This article is educational information about a research-use-only compound. It is not guidance for use in people or animals; anyone with a question about an animal's health should talk to their veterinarian, and anyone with a personal health question should talk to a licensed physician.

Verifying and storing a non-peptide compound in the lab

Every batch should arrive with a lot-specific certificate of analysis showing HPLC purity and mass spectrometry identity confirmation consistent with the expected molecular weight near 304 g/mol. A generic certificate with no lot number tying it to the vial in your hand is decoration, not documentation.

Storage is simpler than peptide handling and considerably more forgiving. Bromantane is a stable crystalline solid: cool, dry, dark, tightly sealed and desiccated is the baseline, with freezer storage around -20 C for long-term archival stock. The failure mode here is moisture ingress and light exposure, not protein denaturation, so the discipline that matters is minimising vial opening and letting cold material equilibrate to room temperature before breaking the seal. Sound bromantane research starts with a sample whose provenance you can prove.

Real Peptides supplies bromantane as part of our oral research compounds collection, with third-party certificates of analysis published for reference and full catalog plus facility and shipping details available for procurement teams. The same small-batch synthesis and verification standard applies across the line, whether the material is a small molecule like this one or a peptide such as Selank or 5-Amino-1MQ.

How the evidence base compares with other lab compounds

Researchers rarely evaluate one compound in isolation, and the useful comparison isn't potency. It's how much published evidence exists, what regulatory status follows from it, and what the material demands of your storage protocol.

Compound	Where the evidence sits	Regulatory status	Laboratory handling	Bottom line for researchers
Bromantane (adamantane derivative)	Mostly Russian-language clinical and preclinical work on asthenia and anxiety, limited independent replication	Registered historically in Russia, not FDA or EMA reviewed, prohibited in sport as a stimulant	Stable solid, no reconstitution, cool and dry with desiccant, -20 C for archival stock	Interesting mechanism with a thin English-language record; design repeated-administration studies, not acute ones
Selank (heptapeptide)	Russian preclinical and clinical literature on anxiolytic and neuroimmune endpoints	Not FDA approved, research use only in most markets	Liquid or lyophilised formats, refrigerated, sensitive to temperature excursion	Shares bromantane's Russian paper trail; useful comparator for anxiolytic mechanism work
BPC-157 (pentadecapeptide)	Extensive rodent preclinical literature, minimal published human trial data	Not FDA approved, prohibited in sport	Lyophilised, frozen before reconstitution, refrigerated 2 to 8 C once mixed	Deep animal dataset, shallow human dataset; the opposite evidence shape to bromantane
5-Amino-1MQ (NNMT inhibitor)	Preclinical metabolic and adipocyte work, no published human trials	Not FDA approved, research use only	Stable oral-format solid, room temperature tolerant, desiccated storage	Mechanistically well defined but early stage; handling profile closest to bromantane

What If: Common Laboratory Scenarios

What if the powder looks off-white rather than pure white?

Log the observation, then verify against the lot-specific certificate rather than judging by eye. Adamantane derivatives commonly present as white to off-white crystalline solids, and colour is not a purity assay. HPLC purity and mass spectrometry identity are the only checks that settle the question. Colour that shifts during storage is a different signal entirely, and usually points to moisture ingress or light exposure rather than an original quality problem.

What if the only primary sources are in Russian?

Budget translation time into the protocol and read for method rather than conclusions. Much of bromantane research exists as Russian-language clinical papers plus review articles summarising that same earlier work, so citation chains loop back on themselves quickly. Check whether the paper reports randomisation, blinding, sample size and a predefined endpoint. If those elements are missing, you're reading a clinical report, not a controlled trial, and it should be weighted accordingly.

What if a single-dose assay shows no measurable effect?

Interrogate the study design before discarding the compound. The biosynthesis-side mechanism described in published bromantane research builds across repeated administration, so an acute observation window borrowed from stimulant pharmacology can produce a null result that reflects timing rather than inactivity. Repeated-administration designs with an appropriate washout period align far better with what the literature actually describes.

What if a supplier can't produce a batch-specific certificate?

Treat it as disqualifying and source elsewhere. A generic analytical document with no lot number cannot be tied to the material you received, which makes every downstream result in your dataset unverifiable at the first point of the chain. Third-party analysis per batch is the minimum standard for any research compound, and suppliers who publish it openly are signalling that they expect the documents to be read.

The blunt answer on safety and dosage claims

Let's be direct about this: nobody can give a safe bromantane dose, because no regulator has established one and no adequately powered published trial supports one. Aggregator pages ranking for bromantane dosage, including the figures circulating via WholisticResearch and similar sites, compile numbers from animal studies, Russian trial ranges and anecdote, then present the blend as guidance. We don't publish administration protocols for any research compound. A number being easy to find doesn't make it validated. The useful question in bromantane research was never how much. It's what was measured, in whom, and by whom.

Bromantane research is a case study in how a compound acquires a reputation faster than it acquires evidence. Four decades after the first Soviet work and three after Atlanta, the English-language record remains thin enough that a careful reader can work through most of it in an afternoon. That isn't a reason to dismiss the compound; some of the most interesting pharmacology sits in exactly these under-examined corners. It is a reason to treat every confident claim as a hypothesis with a citation attached, and to check where that citation actually leads before building a protocol around it.

References

Peer-reviewed sources on Bromantane indexed in PubMed, listed for research context. Real Peptides supplies Bromantane for laboratory research use only.

Correcting effect of ladasten on variations in the subpopulation composition of T lymphocytes in C57BL/6 mice on the experimental model of an anxious-depressive state. Bulletin of experimental biology and medicine, 2014. PMID 24771370. doi:10.1007/s10517-014-2343-1
[Ladasten versus placebo effect self-evaluated by neurasthenia patients with different EEG alpha rhythm types]. Eksperimental'naia i klinicheskaia farmakologiia, 2012. PMID 22834121
Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases. Bulletin of experimental biology and medicine, 2012. PMID 22803074. doi:10.1007/s10517-012-1516-z
Effect of ladasten on the content of cytokine markers of inflammation and behavior of mice with experimental depression-like syndrome. Bulletin of experimental biology and medicine, 2011. PMID 22803040. doi:10.1007/s10517-011-1453-2
[Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice]. Eksperimental'naia i klinicheskaia farmakologiia, 2011. PMID 22288152
Time course of histone deacetylase 1 and acetylated H3 and H4 histones in the brain of rats treated with ladasten. Bulletin of experimental biology and medicine, 2011. PMID 22235395. doi:10.1007/s10517-011-1201-7
[Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb]. Eksperimental'naia i klinicheskaia farmakologiia, 2010. PMID 20369592
[Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015]. Eksperimental'naia i klinicheskaia farmakologiia, 2010. PMID 20408420

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

There is no evidence base sufficient to call bromantane safe for human use. It has never been reviewed by the FDA or EMA, its clinical record sits almost entirely in small Russian-language studies of asthenic disorders, and long-term exposure data is absent. It is supplied for laboratory research only, never for consumption.

The published literature describes indirect dopaminergic action through biosynthesis rather than reuptake inhibition. Reported effects include upregulated tyrosine hydroxylase, the rate-limiting enzyme converting L-tyrosine to L-DOPA, and aromatic L-amino acid decarboxylase, which converts L-DOPA to dopamine. Because the effect operates at the enzyme expression level, described effects build across repeated administration rather than acutely.

Yes, but the record is narrow. Clinical work was conducted in Russia on asthenic disorders, where the compound was registered as Ladasten, with additional reported investigation in generalised anxiety. These publications are mostly Russian-language, generally small, and rarely replicated independently. No large English-language randomised controlled trial has been published.

Research-use-only compounds are sold to qualified researchers, laboratories and institutions for in-vitro and laboratory investigation. They are not sold for human or veterinary consumption, and suppliers should state that restriction plainly. Purchasers are responsible for confirming the regulatory status of any compound in their own jurisdiction before ordering.

Pricing varies widely by quantity, purity specification and supplier, so any single figure quoted online is unreliable. The more useful question is what the price includes: batch-specific HPLC purity data, mass spectrometry identity confirmation, and accessible third-party documentation. A cheaper vial with no lot-linked certificate is not a saving, because unverified material invalidates downstream results.

Yes. Bromantane is listed by the World Anti-Doping Agency as a prohibited stimulant, a listing that followed positive tests at the 1996 Atlanta Olympics. The Court of Arbitration for Sport cleared those athletes at the time because the compound wasn't yet listed. A doping ban reflects competition integrity policy, not a toxicological safety assessment.

Bromantane is a small lipophilic molecule, while Selank and BPC-157 are peptides with amino acid sequences. That changes everything about handling: peptides typically require frozen storage before reconstitution and refrigeration afterwards, whereas bromantane is a stable solid needing only cool, dry, dark, desiccated conditions. Selank shares bromantane's Russian research lineage; BPC-157 has a much larger rodent preclinical dataset.

Store the solid cool, dry, dark, tightly sealed and desiccated, with freezer storage around -20 C for long-term archival stock. The relevant failure modes are moisture ingress and light exposure rather than protein denaturation. Let cold material equilibrate to room temperature before opening the container to prevent condensation forming on the solid.

It should show a lot or batch number matching the vial, HPLC purity results, and mass spectrometry identity confirmation consistent with the expected molecular weight near 304 g/mol. Ideally the analysis is performed by an independent third-party laboratory. A generic certificate with no batch identifier cannot be tied to the material received and should be treated as unusable.

No. Bromantane has never been approved by the FDA for any indication and is not an approved drug product in the United States. Its historical registration was in Russia under the trade name Ladasten. Material available today is sold as a research compound for laboratory investigation and carries no approval for human or veterinary use.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA